Twist Bioscience Corporation Available-for-sale Securities, Amortized Cost Basis
Twist Bioscience Corporation (TWST) had Available-for-sale Securities, Amortized Cost Basis of $196.32 million as of 2020-09-30, per its 10-K filed 2020-11-27.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2020-11-27
- 2020-09-30: Available-for-sale Securities, Amortized Cost Basis $196.32M.
- 2019-09-30: Available-for-sale Securities, Amortized Cost Basis $91.32M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2020-09-30 | $196.32M 10-K · filed 2020-11-27 |
| 2019-09-30 | $91.32M 10-K · filed 2020-11-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |